Intel Corporation shares declined 2.85% on Friday, closing at $89.47 as investors weighed encouraging progress in the company’s next-generation 14A process against continued losses in its foundry business.

The stock finished the session after 86.17 million shares changed hands. While recent manufacturing data have strengthened the outlook for Intel’s technology roadmap, the company still faces significant financial pressure as it works to build its contract manufacturing business.

14A Defect Density Shows Encouraging Progress

Intel’s 14A process is showing stronger-than-expected progress in defect density, an important measure of manufacturing performance. Chief Financial Officer David Zinsner said defect density is improving faster than the company’s internal target curve.

He also indicated that Intel has not seen comparable progress in this area since its 22nm process.

Defect density measures the number of imperfections across a given area of a wafer. As defect density declines, manufacturers can potentially achieve better yields, lower production costs and more efficient use of manufacturing capacity.

However, the latest improvement remains an early-stage indicator rather than proof that Intel has achieved profitable production at scale.

Intel currently expects to begin 14A risk production in the second half of 2027, followed by high-volume manufacturing in 2028. The commercial ramp will therefore remain an important milestone for investors watching the company’s foundry strategy.

Foundry Revenue Rises, but Losses Remain Heavy

Intel Foundry generated $5.77 billion in revenue during the second quarter, representing 31% growth from the same period a year earlier. Despite the stronger revenue performance, the segment recorded an operating loss of $2.09 billion.

The second-quarter loss was an improvement from the $3.17 billion operating loss reported a year earlier. Even so, the latest loss represented about 36.2% of the segment’s quarterly revenue, highlighting the financial challenge facing Intel’s manufacturing operations.

The contrast between rising revenue and continuing losses remains a key issue for investors. Intel needs its manufacturing investments to eventually translate into stronger margins and improved returns as production capacity expands.

Core Businesses Continue to Support Investment

Intel’s product businesses remain an important source of support while the company invests heavily in its foundry operations.

Data Center and AI revenue increased 59% to $6.3 billion in the second quarter, while client revenue rose 13% to $8.9 billion.

Across the company, revenue climbed 25% to $16.1 billion. Intel also reported a non-GAAP gross margin of 41.8% and operating cash flow of $7 billion.

The stronger performance in its core product businesses provides Intel with financial resources to continue investing in advanced manufacturing technologies. At the same time, the scale of the foundry losses shows that the transition will require substantial spending before the business can deliver sustained profitability.

Customer Interest Moves Toward Capacity

Intel is also seeing signs of more serious interest in its 14A manufacturing technology.

According to Zinsner, conversations with potential external customers have moved beyond simply evaluating Intel’s process technology. Discussions are increasingly focused on how much 14A manufacturing capacity Intel could make available.

That shift could become significant if customers eventually commit to production. However, Intel’s planned 2027 risk production and 2028 high-volume manufacturing timelines mean commercial validation is still ahead.

High-NA EUV Plays a Key Role

High-NA extreme ultraviolet lithography is central to Intel’s 14A manufacturing strategy. The technology is designed to enable smaller features and greater pattern density compared with existing EUV systems.

Intel expects the advanced lithography platform to play an important role in producing chips using its 14A process. Its performance and cost will therefore be closely tied to the company’s ability to improve manufacturing economics.

Analysts Remain Cautious Despite Upside Target

Investor sentiment remains mixed. Among 50 tracked analysts, 16 have a buy rating, 31 have a hold rating and three have a sell rating.

The average analyst price target stands at $107.46, which is around 20.1% above Intel’s Friday closing price of $89.47.

For investors, the central question is whether Intel can convert its improving 14A manufacturing performance into commercially viable production. Falling defect density is an encouraging development, but it does not automatically translate into production yields or profitability.

Intel still faces potential challenges including manufacturing delays, weaker-than-expected external demand and the high costs associated with advanced High-NA equipment. The company’s ability to maintain its technology progress while reducing foundry losses will remain critical as it moves toward 14A risk production in 2027 and volume manufacturing in 2028.

Also Read: Inside Breedr: Ian Wheal’s $27M Push to Digitize Cattle, One Animal at a Time